Thousand Oaks-based Amgen beat analysts’ expectations when it reported its earnings for the second quarter on Aug. 3, but more importantly, the company reaffirmed its position that it can close the pending acquisition of Horizon Therapeutics before the end of the year. The biotech giant reported net income grew 4.5% year over year from $1.32
Thousand Oaks-based Amgen delivered a sound earnings beat in the first quarter of 2023, the company announced after the markets closed on April 27. Amgen, one of the largest biotechnology companies in the world, generated net income worth $2.8 billion in the first quarter or $5.28 earnings per share. This nearly doubled last year’s first-quarter